BeOne Medicines (NASDAQ:ONC – Get Free Report) and Aurora Cannabis (NASDAQ:ACB – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, analyst recommendations and institutional ownership.
Insider & Institutional Ownership
48.5% of BeOne Medicines shares are held by institutional investors. Comparatively, 47.6% of Aurora Cannabis shares are held by institutional investors. 6.2% of BeOne Medicines shares are held by insiders. Comparatively, 0.0% of Aurora Cannabis shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares BeOne Medicines and Aurora Cannabis”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BeOne Medicines | $6.13 billion | 6.35 | $286.93 million | $5.68 | 62.37 |
| Aurora Cannabis | $314.07 million | 0.94 | -$88.13 million | ($1.41) | -3.19 |
BeOne Medicines has higher revenue and earnings than Aurora Cannabis. Aurora Cannabis is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
BeOne Medicines has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500. Comparatively, Aurora Cannabis has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for BeOne Medicines and Aurora Cannabis, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BeOne Medicines | 0 | 3 | 12 | 2 | 2.94 |
| Aurora Cannabis | 1 | 2 | 1 | 0 | 2.00 |
BeOne Medicines currently has a consensus target price of $404.93, suggesting a potential upside of 14.30%. Given BeOne Medicines’ stronger consensus rating and higher probable upside, research analysts clearly believe BeOne Medicines is more favorable than Aurora Cannabis.
Profitability
This table compares BeOne Medicines and Aurora Cannabis’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BeOne Medicines | 10.70% | 14.23% | 7.82% |
| Aurora Cannabis | -32.26% | 4.37% | 3.45% |
Summary
BeOne Medicines beats Aurora Cannabis on 14 of the 15 factors compared between the two stocks.
About BeOne Medicines
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.
About Aurora Cannabis
Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.
Receive News & Ratings for BeOne Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeOne Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
